Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

[1]  M. Sydes,et al.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.

[2]  G. D. De Keulenaer,et al.  Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity , 2018, Clinical and Experimental Pharmacology and Physiology.

[3]  Babak Otoukesh,et al.  Novel molecular insights and new therapeutic strategies in osteosarcoma , 2018, Cancer Cell International.

[4]  Sung-Bae Kim,et al.  Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Woolard,et al.  Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma , 2018, Veterinary and comparative oncology.

[6]  C. Hawkins,et al.  Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. , 2018, Veterinary and comparative oncology.

[7]  R. Korneluk,et al.  Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression , 2018, Molecular therapy oncolytics.

[8]  S. Dougan,et al.  Regulation of innate and adaptive antitumor immunity by IAP antagonists. , 2018, Immunotherapy.

[9]  Shreyaskumar R Patel,et al.  Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment , 2018, Current Oncology Reports.

[10]  T. Martin,et al.  Murine models of osteosarcoma: A piece of the translational puzzle , 2018, Journal of cellular biochemistry.

[11]  D. Heymann,et al.  Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations , 2018, Journal of bone oncology.

[12]  M. Kurosaka,et al.  Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma. , 2017, Anticancer research.

[13]  V. Naumenko,et al.  Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms , 2017, Nature Communications.

[14]  G. Churchill,et al.  Genetic Background Influences Susceptibility to Chemotherapy-Induced Hematotoxicity , 2017, The Pharmacogenomics Journal.

[15]  L. Mirabello,et al.  Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy , 2017, Nature Reviews Endocrinology.

[16]  Reed Dm,et al.  Re-calculating! Navigating through the osteosarcoma treatment roadblock. , 2017 .

[17]  T. Alain,et al.  Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma , 2017, Nature Communications.

[18]  R. Korneluk,et al.  Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model , 2016, Oncotarget.

[19]  Y. Asmann,et al.  IAP antagonists induce anti-tumor immunity in multiple myeloma , 2016, Nature Medicine.

[20]  X. Zang,et al.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.

[21]  A. Abarrategi,et al.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies , 2016, Stem cells international.

[22]  Ankita Gupte,et al.  IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα , 2016, Oncotarget.

[23]  C. Meazza,et al.  Metastatic osteosarcoma: a challenging multidisciplinary treatment , 2016, Expert review of anticancer therapy.

[24]  L. Spector,et al.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison , 2016, Pediatric blood & cancer.

[25]  E. Kohn,et al.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer , 2016, Cancer.

[26]  S. Fulda.  Promises and Challenges of Smac Mimetics as Cancer Therapeutics , 2015, Clinical Cancer Research.

[27]  S. Fulda,et al.  Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. , 2015, Cancer letters.

[28]  A. Adjei,et al.  A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma , 2015, Molecular Cancer Therapeutics.

[29]  P. Hertzog,et al.  Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer , 2015, Cancer Immunology Research.

[30]  R. Larson,et al.  Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. , 2015, Clinical lymphoma, myeloma & leukemia.

[31]  B. Fuchs,et al.  Genomic Instability of Osteosarcoma Cell Lines in Culture: Impact on the Prediction of Metastasis Relevant Genes , 2015, PloS one.

[32]  Ying-jian Liang,et al.  GDC-0152 attenuates the malignant progression of osteosarcoma promoted by ANGPTL2 via PI3K/AKT but not p38MAPK signaling pathway. , 2015, International journal of oncology.

[33]  B. Fuchs,et al.  Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam , 2015, Laboratory animals.

[34]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[35]  J. Infante,et al.  Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Saya,et al.  TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state , 2014, Oncogene.

[37]  A. Chalk,et al.  Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo , 2014, Oncogene.

[38]  S. Ghivizzani,et al.  Animal Models in Osteosarcoma , 2014, Front. Oncol..

[39]  James M. Bogenberger,et al.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. , 2014, Journal of the National Cancer Institute.

[40]  Wenjie Zheng,et al.  Effect of the cytokine levels in serum on osteosarcoma , 2014, Tumor Biology.

[41]  S. Fulda,et al.  Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis , 2013, Cell Death and Disease.

[42]  Dajun Yang,et al.  Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma , 2013, Molecular Cancer Therapeutics.

[43]  David P. Taylor,et al.  Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. , 2013, American journal of veterinary research.

[44]  S. Koernig,et al.  Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy , 2013, Cancer Immunology, Immunotherapy.

[45]  Shuijun Zhang,et al.  Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells , 2012, PloS one.

[46]  S. Libutti,et al.  Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity , 2012, Cancer Gene Therapy.

[47]  Delong Liu,et al.  Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis , 2012, Experimental Hematology & Oncology.

[48]  S. Keir,et al.  Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[49]  Zhaoyang Wen,et al.  Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). , 2012, Journal of medicinal chemistry.

[50]  A. Alfaro-Rodríguez,et al.  Serum tumor markers in pediatric osteosarcoma: a summary review , 2012, Clinical Sarcoma Research.

[51]  M. Darding,et al.  IAPs: Guardians of RIPK1 , 2011, Cell Death and Differentiation.

[52]  H. Gelderblom,et al.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? , 2011, European journal of cancer.

[53]  A. Llombart‐Bosch,et al.  Functional characterization of osteosarcoma cell lines provides representative models to study the human disease , 2011, Laboratory Investigation.

[54]  Shaomeng Wang,et al.  Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[55]  Anne-Marie Cleton-Jansen,et al.  Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.

[56]  D. McConkey,et al.  Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells , 2010, Cancer biology & therapy.

[57]  G. Gores,et al.  A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)‐induced invasion and metastasis of cholangiocarcinoma cells , 2010, Hepatology.

[58]  M. Bolognesi,et al.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib , 2010, British Journal of Cancer.

[59]  T. Lawrence,et al.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB , 2009, BMC Cancer.

[60]  L. Donehower,et al.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.

[61]  U. Bhanot,et al.  Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. , 2009, Cancer research.

[62]  David P. Taylor,et al.  Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. , 2009, American journal of veterinary research.

[63]  S. Fulda,et al.  Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. , 2008, Cancer research.

[64]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[65]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[66]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[67]  J. Minna,et al.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. , 2007, Cancer cell.

[68]  G. Salvesen,et al.  The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.

[69]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[70]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[71]  P. Vandenabeele,et al.  Identification of Tumor Necrosis Factor (TNF) Amino Acids Crucial for Binding to the Murine p75 TNF Receptor and Construction of Receptor-selective Mutants* , 2001, The Journal of Biological Chemistry.

[72]  G. Bancroft,et al.  Early Nonspecific Immune Responses and Immunity to Blood-Stage Nonlethal Plasmodium yoelii Malaria , 2000, Infection and Immunity.

[73]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[74]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[75]  M. Dewhirst,et al.  Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. , 1999, Cancer research.

[76]  C. Radzikowski,et al.  Cytotoxic cells in immunodeficient athymic mice. , 1994, Immunopharmacology and immunotoxicology.

[77]  C. Bucana,et al.  Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. , 1994, The American journal of pathology.

[78]  B. Aggarwal,et al.  Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. , 1988, Cancer research.

[79]  W. Fiers,et al.  Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors. , 1986, The Journal of biological chemistry.

[80]  P. Czabotar,et al.  The Structural Basis of Necroptotic Cell Death Signaling. , 2019, Trends in biochemical sciences.

[81]  Jian Jiang,et al.  SMAC mimetic SM-164 enhanced adriamycin induced apoptosis and cell cycle arrest in osteosarcoma cell line HOS , 2017 .

[82]  S. Fulda.  Smac Mimetics to Therapeutically Target IAP Proteins in Cancer. , 2017, International review of cell and molecular biology.

[83]  J. Silke,et al.  IAPs and Cell Death. , 2017, Current topics in microbiology and immunology.

[84]  D. Reed,et al.  Re‐calculating! Navigating through the osteosarcoma treatment roadblock , 2017, Pharmacological research.

[85]  Megan E Anderson.  Update on Survival in Osteosarcoma. , 2016, The Orthopedic clinics of North America.

[86]  M. Leverkus,et al.  Characterization of the ripoptosome and its components: implications for anti-inflammatory and cancer therapy. , 2014, Methods in enzymology.

[87]  W. Fairbrother,et al.  Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[88]  J. Allensworth,et al.  Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism , 2012, Breast Cancer Research and Treatment.

[89]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[90]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[91]  Xiaodong Wang,et al.  A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. , 2004, Science.

[92]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..